{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:43:32Z","timestamp":1790009012307,"version":"4.0.1"},"reference-count":14,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:00:00Z","timestamp":1501718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:p>The aim of this non\u2010interventional, multi\u2010database, analytical cohort study was to assess the cardiovascular (CV) safety of vildagliptin vs other non\u2010insulin antidiabetic drugs (NIADs) using real\u2010world data from 5 European electronic healthcare databases. Patients with type 2 diabetes aged \u226518 years on NIAD treatment were enrolled. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (CIs) for the outcomes of interest (myocardial infarction [MI], acute coronary syndrome [ACS], stroke, congestive heart failure [CHF], individually and as a composite) were estimated using negative binomial regression. Approximately 2.8% of the enrolled patients (n = 738 054) used vildagliptin at any time during the study, with an average follow\u2010up time of 1.4 years, resulting in a cumulative current vildagliptin exposure of 28 330 person\u2010years. The adjusted IRRs (vildagliptin [\u00b1other NIADs] vs other NIADs) were in the range of 0.61 to 0.97 (MI), 0.55 to 1.60 (ACS), 0.02 to 0.77 (stroke), 0.49 to 1.03 (CHF), and 0.22 to 1.02 (composite CV outcomes). The IRRs and their 95% CIs were close to 1, demonstrating no increased risk of adverse CV events, including the risk of CHF, with vildagliptin vs other NIADs in real\u2010world conditions.<\/jats:p>","DOI":"10.1111\/dom.12951","type":"journal-article","created":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T11:06:02Z","timestamp":1490353562000},"page":"1473-1478","source":"Crossref","is-referenced-by-count":25,"title":["Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi\u2010database, non\u2010interventional post\u2010authorization safety study"],"prefix":"10.1111","volume":"19","author":[{"given":"Rachael","family":"Williams","sequence":"first","affiliation":[{"name":"Clinical Practice Research Datalink  London UK"},{"name":"Utrecht Institute for Pharmaceutical Sciences Utrecht University  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"de Vries","sequence":"additional","affiliation":[{"name":"Utrecht Institute for Pharmaceutical Sciences Utrecht University  Utrecht The Netherlands"},{"name":"Department of Clinical Pharmacy and Toxicology Maastricht University Medical Centre+  Maastricht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Kothny","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Serban","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lopez\u2010Leon","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changan","family":"Chu","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey"},{"name":"Sanofi\u2010Aventis US LLC  Bridgewater New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5160-0872","authenticated-orcid":false,"given":"Raymond","family":"Schlienger","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"IDF Diabetes","author":"International Diabetes Federation","year":"2015"},{"key":"e_1_2_6_3_1","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research.Guidance for industry: diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.2008.www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071627.pdf. Accessed April 19 2016."},{"key":"e_1_2_6_4_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP).Concept paper on the need for revision of the note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus.2008.www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003182.pdf. Accessed April 19 2016."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-016-0744-4"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305889"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12548"},{"issue":"1","key":"e_1_2_6_10_1","first-page":"A265","article-title":"No significant difference in risk of heart failure hospitalization with vildagliptin in diabetic patients with systolic chronic heart failure: VIVIDD Study","volume":"63","author":"Krum H","year":"2014","journal-title":"Diabetes"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001358"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP47617"},{"issue":"4","key":"e_1_2_6_13_1","first-page":"445","article-title":"The Danish prescription registries","volume":"44","author":"Gaist D","year":"1997","journal-title":"Dan Med Bull"},{"key":"e_1_2_6_14_1","unstructured":"The National Board of Health and Welfare Sweden.http:\/\/www.socialstyrelsen.se\/register\/halsodataregister\/patientregistret\/inenglish. Accessed July 15 2016."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1191\/0962280204sm363ra"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12951","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:37:07Z","timestamp":1761885427000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1111\/dom.12951"],"URL":"https:\/\/doi.org\/10.1111\/dom.12951","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,3]]}}}